Hologic, Inc. (HOLX) Given Consensus Recommendation of “Buy” by Analysts

Hologic, Inc. (NASDAQ:HOLX) has earned an average recommendation of “Buy” from the fifteen brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $47.54.

A number of equities research analysts recently weighed in on HOLX shares. Needham & Company LLC reaffirmed a “buy” rating on shares of Hologic in a report on Tuesday, August 1st. BidaskClub lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Royal Bank Of Canada lowered their price target on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a report on Thursday, August 3rd. Goldman Sachs Group Inc lowered shares of Hologic from a “conviction-buy” rating to a “buy” rating and lowered their price target for the company from $48.00 to $47.00 in a report on Thursday, August 3rd. Finally, Deutsche Bank AG lowered their price target on shares of Hologic from $51.00 to $49.00 and set a “buy” rating for the company in a report on Thursday, August 3rd.

Shares of Hologic (NASDAQ HOLX) opened at $40.87 on Monday. Hologic has a 52-week low of $35.76 and a 52-week high of $46.80. The stock has a market cap of $11,267.20, a price-to-earnings ratio of 20.23, a PEG ratio of 1.98 and a beta of 0.93. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.79.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.01. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The company had revenue of $802.90 million during the quarter, compared to analyst estimates of $792.54 million. During the same quarter in the prior year, the business earned $0.52 earnings per share. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. research analysts forecast that Hologic will post 2.12 EPS for the current fiscal year.

In other news, Director Lawrence M. Levy sold 9,596 shares of the firm’s stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $36.81, for a total value of $353,228.76. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Lawrence M. Levy sold 7,138 shares of the firm’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $37.38, for a total transaction of $266,818.44. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,972 shares of company stock valued at $1,385,977. 0.79% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the company. Grove Bank & Trust lifted its position in Hologic by 115.8% in the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after purchasing an additional 1,535 shares during the last quarter. Hall Laurie J Trustee lifted its position in Hologic by 10.2% in the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after purchasing an additional 225 shares during the last quarter. Commonwealth Bank of Australia lifted its position in Hologic by 31.0% in the 2nd quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after purchasing an additional 600 shares during the last quarter. MPS Loria Financial Planners LLC bought a new stake in Hologic in the 2nd quarter valued at about $191,000. Finally, National Asset Management Inc. bought a new stake in Hologic in the 2nd quarter valued at about $203,000. Institutional investors own 97.72% of the company’s stock.

WARNING: This report was first posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://transcriptdaily.com/2017/11/27/hologic-inc-holx-given-consensus-recommendation-of-buy-by-analysts.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply